Reduced HIV-stimulated T-helper cell reactivity in cord blood with short-course antiretroviral treatment for prevention of maternal-infant transmission

Clinical and Experimental Immunology

Volumn 123, Issue 3, 2001, Pages 443-450

  Kuhn, L ^a   Meddows Taylor, S ^a   Gray, G ^a  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

Author keywords

Antiretroviral treatment; Cellular immunity; Human immunodeficiency virus; Interleukin 2; Maternal infant transmission

Indexed keywords

ANTIRETROVIRUS AGENT; INTERLEUKIN 2; LAMIVUDINE; VIRUS ANTIGEN; VIRUS ENVELOPE PROTEIN; VIRUS RNA; ZIDOVUDINE;

ADULT; ARTICLE; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOREACTIVITY; INFANT; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UMBILICAL CORD BLOOD; VERTICAL TRANSMISSION; VIRUS INHIBITION; VIRUS TRANSMISSION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; CLINICAL TRIALS; DISEASE TRANSMISSION, VERTICAL; FEMALE; FETAL BLOOD; GENE PRODUCTS, ENV; HIV INFECTIONS; HUMANS; INFANT, NEWBORN; LAMIVUDINE; MALE; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; SOUTH AFRICA; T-LYMPHOCYTES, HELPER-INDUCER; ZIDOVUDINE;

EID: 0035069207     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2001.01460.x     Document Type: Article

References (45)

1. Protective immunity against HIV infection: Has nature done the experiment for us?
2. HIV type 1-specific helper T cells: A critical host defense
3. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1
4. Human immunodeficiency virus type 1 (HIV-1) -seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelop
5. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
6. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
7. HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers
8. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood
9. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients
10. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids
11. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant
12. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-1-infected mothers
13. Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection
14. Occurrence of human immuno-deficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers
15. High frequency of Gag- and envelope-specific cytotoxic T lymphocyte precursors in children with vertically acquired human immunodeficiency virus type 1 infection
16. Deficient human immunodeficiency virus type 1-specific cytotoxic T cell responses in vertically infected children
17. Protective role of B-chemokines associated with HIV-specific Th responses against perinatal HIV transmission
18. Cellular immune factors associated with mother-to-infant transmission of HIV
19. T-helper cell responses to HIV envelope peptides in cord blood: Protection against intrapartum and breastfeeding transmission
20. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomized controlled trial
21. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte D'Ivoire: A randomized trial
22. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breast fed children in Côte d'Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial
23. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant
24. Results of the PETRA intervention trial to prevent perinatal transmission in sub-Saharan Africa
25. The PETRA study: Early and late efficacy of three short ZDV/3TC combination regimens to prevent mother-to-child transmission of HIV-1
26. Interleukin-2 production used to detect antigenic peptide recognition by T-helper lymphocytes from asymptomatic HIV-seropositive individuals
27. Exposure to human immunodeficiency virus type 1-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies
28. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types
29. T cell multideterminant regions in the human immunodeficiency virus envelop: Toward overcoming the problem of major histocompatibility complex restriction
30. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelop protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide
31. Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages
32. Different immunologic profiles characterize HIV infection in highly active antiretroviral therapy-treated and antiretroviral-naive patients with undetectable viraemia
33. Cell growth factor: Parameters of production and a quantitative microassay for activity
34. Long-term culture of tumor-specific cytotoxic T cells
35. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring
36. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses
37. Administration of zidovudine during primary HIV-1 infection may be associated with a less vigorous immune response
38. T-cell function in newborn mice and humans
39. T-cell proliferation to subinfectious SIV correlates with lack of infection after challenge of macaques
40. Analysis of neonatal T cell and antigen presenting cell functions
41. Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workers
42. Differential effect of azidothymidine on resting and activated cells: Potentiality of this drug for treatment of post-transfusion graft-versus-host disease
43. Rapid disease progression in HIV-1 perinatally infected children born to mothers receiving zidovudine monotherapy during pregnacy
44. Disease progression and early viral dynamics in HIV-infected children exposed to zidovudine during the pre- and peri-natal period
45. 15-Month efficacy of maternal oral zidovudine to decrease vertical transmission of HIV-1 in breastfed African children